These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 26896194)

  • 21. Preformed donor-specific HLA antibodies are associated with increased risk of early mortality after liver transplantation.
    McCaughan JA; Robertson V; Falconer SJ; Cryer C; Turner DM; Oniscu GC
    Clin Transplant; 2016 Dec; 30(12):1538-1544. PubMed ID: 27653177
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pretransplant angiotensin II type 1-receptor antibodies are a risk factor for earlier detection of de novo HLA donor-specific antibodies.
    Cuevas E; Arreola-Guerra JM; Hernández-Méndez EA; Salcedo I; Castelán N; Uribe-Uribe NO; Vilatobá M; Contreras-Saldívar AG; Sánchez-Cedillo AI; Ramírez JB; de Rungs D; Granados J; Morales-Buenrostro LE; Alberú J
    Nephrol Dial Transplant; 2016 Oct; 31(10):1738-45. PubMed ID: 27220757
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of living donor liver transplantation varies with the availability of deceased donor liver transplantation.
    Vagefi PA; Ascher NL; Freise CE; Dodge JL; Roberts JP
    Liver Transpl; 2012 Feb; 18(2):160-5. PubMed ID: 22006378
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Living vs. deceased donor liver transplantation provides comparable recovery of renal function in patients with hepatorenal syndrome: a matched case-control study.
    Goldaracena N; Marquez M; Selzner N; Spetzler VN; Cattral MS; Greig PD; Lilly L; McGilvray ID; Levy GA; Ghanekar A; Renner EL; Grant DR; Selzner M
    Am J Transplant; 2014 Dec; 14(12):2788-95. PubMed ID: 25277134
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence, Risk Factors, and Impact of Donor-Specific Alloantibodies After Adult Liver Transplantation.
    Vandevoorde K; Ducreux S; Bosch A; Guillaud O; Hervieu V; Chambon-Augoyard C; Poinsot D; André P; Scoazec JY; Robinson P; Boillot O; Dubois V; Dumortier J
    Liver Transpl; 2018 Aug; 24(8):1091-1100. PubMed ID: 29665189
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evolution of donor-specific antibodies (DSA) and incidence of de novo DSA in solid organ transplant recipients after switch to everolimus alone or associated with low dose of calcineurin inhibitors.
    Perbos E; Juinier E; Guidicelli G; Dromer C; Merville P; Billes MA; Taupin JL; Neau-Cransac M
    Clin Transplant; 2014 Sep; 28(9):1054-60. PubMed ID: 25040585
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of pretransplant donor-specific antibodies on kidney allograft recipients with negative flow cytometry cross-matches.
    Kwon H; Kim YH; Choi JY; Shin S; Jung JH; Park SK; Han DJ
    Clin Transplant; 2018 Jun; 32(6):e13266. PubMed ID: 29676812
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcomes of living and deceased donor liver transplant recipients with hepatocellular carcinoma: results of the A2ALL cohort.
    Kulik LM; Fisher RA; Rodrigo DR; Brown RS; Freise CE; Shaked A; Everhart JE; Everson GT; Hong JC; Hayashi PH; Berg CL; Lok AS;
    Am J Transplant; 2012 Nov; 12(11):2997-3007. PubMed ID: 22994906
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development, management, and resolution of biliary complications after living and deceased donor liver transplantation: a report from the adult-to-adult living donor liver transplantation cohort study consortium.
    Zimmerman MA; Baker T; Goodrich NP; Freise C; Hong JC; Kumer S; Abt P; Cotterell AH; Samstein B; Everhart JE; Merion RM
    Liver Transpl; 2013 Mar; 19(3):259-67. PubMed ID: 23495079
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comparison of rates and severity of chronic kidney disease in deceased-donor and living-donor liver transplant recipients: times matter.
    Yankol Y; Bugeaud E; Zens T; Rizzari M; Mecit N; Leverson GE; Foley D; Mezrich JD; Kanmaz T; Andaçoğlu OM; D'Alessandro AM; Acarlı KS; Kalayoğlu M; Fernandez LA
    Turk J Med Sci; 2021 Apr; 51(2):610-622. PubMed ID: 33037873
    [TBL] [Abstract][Full Text] [Related]  

  • 31. One-Year Outcomes of Living Related Kidney Transplant in Patients With Preformed HLA Donor-Specific Antibodies: A Single-Center Experience in Malaysia.
    Jalalonmuhali M; Ng KP; Mohd Shariff NH; Lee YW; Wong AH; Gan CC; Lim SK
    Transplant Proc; 2020; 52(6):1718-1722. PubMed ID: 32448671
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of preformed donor-specific antibodies and C4d on early liver allograft function.
    Perera MT; Silva MA; Murphy N; Briggs D; Mirza DF; Neil DA
    Scand J Gastroenterol; 2013 Dec; 48(12):1444-51. PubMed ID: 24131305
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Poor graft outcome in recipients with de novo donor-specific anti-HLA antibodies after living related kidney transplantation.
    Li X; Ishida H; Yamaguchi Y; Tanabe K
    Transpl Int; 2008 Dec; 21(12):1145-52. PubMed ID: 18803618
    [TBL] [Abstract][Full Text] [Related]  

  • 34. De novo donor-specific anti-HLA antibodies mediated rejection in liver-transplant patients.
    Del Bello A; Congy-Jolivet N; Danjoux M; Muscari F; Lavayssière L; Esposito L; Cardeau-Desangles I; Guitard J; Dörr G; Milongo D; Suc B; Duffas JP; Alric L; Bureau C; Guilbeau-Frugier C; Rostaing L; Kamar N
    Transpl Int; 2015 Dec; 28(12):1371-82. PubMed ID: 26303035
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Graft and patient survival after adult live donor liver transplantation compared to a matched cohort who received a deceased donor transplantation.
    Thuluvath PJ; Yoo HY
    Liver Transpl; 2004 Oct; 10(10):1263-8. PubMed ID: 15376301
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and Efficacy of a Steroid Avoidance Immunosuppression Regimen in Renal Transplant Patients With De Novo or Preformed Donor-Specific Antibodies: A Single-Center Study.
    Schutt R; Case J; Kurian SM; Spierling Bagsic SR; Barrick BL; Toll AE; Zhang Q; Reed EF; Quigley MM; Schaffer R; Fisher JS; Rice JC; Marsh CL
    Transplant Proc; 2021 Apr; 53(3):950-961. PubMed ID: 33293041
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Eplet Mismatch Load and
    Senev A; Coemans M; Lerut E; Van Sandt V; Kerkhofs J; Daniëls L; Driessche MV; Compernolle V; Sprangers B; Van Loon E; Callemeyn J; Claas F; Tambur AR; Verbeke G; Kuypers D; Emonds MP; Naesens M
    J Am Soc Nephrol; 2020 Sep; 31(9):2193-2204. PubMed ID: 32764139
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preformed C1q-binding Donor-specific Anti-HLA Antibodies and Graft Function After Kidney Transplantation.
    Okabe Y; Noguchi H; Miyamoto K; Kaku K; Tsuchimoto A; Masutani K; Nakamura M
    Transplant Proc; 2018 Dec; 50(10):3460-3466. PubMed ID: 30577221
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Defining long-term outcomes with living donor liver transplantation in North America.
    Olthoff KM; Smith AR; Abecassis M; Baker T; Emond JC; Berg CL; Beil CA; Burton JR; Fisher RA; Freise CE; Gillespie BW; Grant DR; Humar A; Kam I; Merion RM; Pomfret EA; Samstein B; Shaked A
    Ann Surg; 2015 Sep; 262(3):465-75; discussion 473-5. PubMed ID: 26258315
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Donor-Recipient Matching Based on Predicted Indirectly Recognizable HLA Epitopes Independently Predicts the Incidence of De Novo Donor-Specific HLA Antibodies Following Renal Transplantation.
    Lachmann N; Niemann M; Reinke P; Budde K; Schmidt D; Halleck F; Pruß A; Schönemann C; Spierings E; Staeck O
    Am J Transplant; 2017 Dec; 17(12):3076-3086. PubMed ID: 28613392
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.